Patent Application Titled "Inhibitors Of The Menin-Mll Interaction" Published Online (USPTO 20230174541).
In: Cancer Weekly, 2023-06-27, S. 1419-1419
serialPeriodical
Zugriff:
The crystalline form of claim 76, wherein the N-ethyl-2-((4-(7-(((1r,4r)-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide bis-hydrochloric acid salt has an XRPD profile substantially as shown in FIG. The crystalline form of claim 76, wherein the crystalline form of the N-ethyl-2-((4-(7-(((1r,4r)-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide bis-hydrochloric acid salt has at least one or two XRPD peaks, in terms of 2-theta, selected from about 4.7°, about 17.0°, and about 19.5°." Rearranged mixed lineage leukemia (MLL-r) involves recurrent translocations of the 11q23 chromosome locus which lead to an aggressive form of acute leukemia with limited therapeutic options. [Extracted from the article]
Copyright of Cancer Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Application Titled "Inhibitors Of The Menin-Mll Interaction" Published Online (USPTO 20230174541).
|
---|---|
Zeitschrift: | Cancer Weekly, 2023-06-27, S. 1419-1419 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1071-7218 (print) |
Schlagwort: |
|
Sonstiges: |
|